Hasmik Harutyunyan

Prof. Hasmik Harutyunyan

Biochemistry, "COBRAIN" Center, Yerevan State Medical University, Yerevan, Armenia
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YKYuriy M. Kositsyn
Yuriy M. Kositsyn
MAMurilo Sander de Abreu
Murilo Sander de Abreu
TKTatiana Kolesnikova
Tatiana Kolesnikova
ALAlexey Lagunin
Alexey Lagunin
Vladimir Vassilievich PoroikovVladimir Vassilievich Poroikov
Vladimir Vassilievich Poroikov
AKAllan V. Kalueff
Allan V. Kalueff
Depression and schizophrenia are two highly prevalent and severely debilitating neuropsychiatric disorders. Both conventional antidepressant and antipsychotic pharmacotherapies are often inefficient clinically, causing multiple side effects and serious patient compliance problems. Collectively, this calls for the development of novel drug targets for treating depressed and schizophrenic patients. Here, we discuss recent translational advances, research tools and approaches, aiming to facilitate innovative drug discovery in this field. Providing a comprehensive overview of current antidepressants and antipsychotic drugs, we also outline potential novel molecular targets for treating depression and schizophrenia. We also critically evaluate multiple translational challenges and summarize various open questions, in order to foster further integrative cross-discipline research into antidepressant and antipsychotic drug development.

12 October 2020 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
GVGayane Sargis Vardanyan
Gayane Sargis Vardanyan
HHHasmik Harutyunyan
Hasmik Harutyunyan
MAMichail Iosif Aghajanov
Michail Iosif Aghajanov
RVRuben Sargis Vardanyan
Ruben Sargis Vardanyan
In recent decades, obesity has become a pandemic disease and appears to be an ultimate medical and social problem. Existing antiobesity drugs show low efficiency and a wide variety of side effects....

1 July 2023 in Neuroscience and Behavioral Physiology
Verified
Journal Article
Closed access
PDF file
HHHasmik Harutyunyan
Hasmik Harutyunyan
SSSimon Saharyan
Simon Saharyan
ASAlla Shaljyan
Alla Shaljyan
ASAnahit Saharyan
Anahit Saharyan
GVGayane Vardanyan
Gayane Vardanyan

22 March 2026 in Neuroscience
Verified
Journal Article
Closed access
HHHasmik Harutyunyan
Hasmik Harutyunyan
RMRuben Minasyan
Ruben Minasyan
AKAllan V. Kalueff
Allan V. Kalueff
KYKonstantin Boris Yenkoyan
Konstantin Boris Yenkoyan

1 April 2017 in Neurochemical Journal
Verified
Journal Article
Closed access
PDF file
HHHasmik Harutyunyan
Hasmik Harutyunyan
AGA. A. Grigoryan
A. A. Grigoryan
HAH. R. Alaverdyan
H. R. Alaverdyan
GVG. S. Vardanyan
G. S. Vardanyan
MAM. I. Aghajanov
M. I. Aghajanov
Peripheral tissue damage or nerve injury often leads to development of pathological pain processes, such as spontaneous pain, hyperalgesia and allodynia that persist for years or decades after all possible tissue healing has occurred. The modification of classic formalin test with two subsequent injections of formalin can be useful to investigate central mechanisms of “pain memory”. To evaluate the effect of analgesia of periphery on central pathways of nociception we used four groups of analgesics: a local anaesthetic-lidocaine, NSAID-diclofenac, a mu-opioid receptor agonist-DAMGO, anticonvulsant with chronic pain-relieving action-gabapentin. We studied the impact of analgesic drugs on acute and chronic pain conditions taking as a basis c-Fos as a pain intensity marker.

1 March 2023 in Neurochemical Journal
Verified
Journal Article
Closed access
PDF file
HHHasmik Harutyunyan
Hasmik Harutyunyan
MAM. I. Aghajanov
M. I. Aghajanov
GVG. S. Vardanyan
G. S. Vardanyan
Pain is one of the most frequent symptoms accompanying diseases. Every type of pain invokes various molecular mechanisms leading to the central effects, and hence the pain response. The plasticity of the nervous system is a unique property enabling it to change the number and quality of neural connections in order to adapt to the environment. This property is the basis of memory, particularly “pain memory”. The formalin test is widely used as an experimental model of biphasic pain in laboratory animals. We supposed that adding the second injection of a noxious agent to the classical test will enhance the pain response and let us observe plastic changes in the central nervous system and in the periphery. The contralateral repetitive injection of formalin and capsaicin to the rat hind paw revealed an increase in pain score in Phase 1 and a decrease in Phase 2. In Freund’s adjuvant injected group the pain score in both phases was increased. Different patterns of spinal cord neuronal activity were observed in formalin, capsaicin, and Freund’s adjuvant injections. Contralateral repetitive administration of formalin and capsaicin, but not Freund’s adjuvant revealed a “pain memory”, a pain response in previously injected but unaffected in the second injection paw. Analysis of the “pain memory” based on our previous studies revealed its overall central character and lack of association with inflammation. Investigations of mechanisms underlying each type of pain and deep analysis of pain memory may open new perspectives to prevent and treat pain.